Paul R. Hinton
IGM Biosciences (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, Glycosylation and Glycoproteins Research, CAR-T cell therapy research, T-cell and B-cell Immunology, Immunotherapy and Immune Responses
Most-Cited Works
- → An Engineered Human IgG1 Antibody with Longer Serum Half-Life(2006)280 cited
- → Engineered Human IgG Antibodies with Longer Serum Half-lives in Primates(2004)273 cited
- → Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants(2021)184 cited
- → Design of humanized antibodies: From anti-Tac to Zenapax(2005)87 cited
- → Amphiregulin and Epidermal Hyperplasia(2005)52 cited
- → Properties and pharmacokinetics of two humanized antibodies specific for L-selectin(1999)15 cited
- → The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site(2011)15 cited
- → High Avidity IgM-Based CD20xCD3 Bispecific Antibody (IGM-2323) for Enhanced T-Cell Dependent Killing with Minimal Cytokine Release(2019)15 cited
- → Igm-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile(2022)8 cited
- → An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV(2023)3 cited